The ERG test triggered epicardial coronary spasm in more than 40% of Japanese patients who underwent diagnostic angiography for assessment of stable angina and unobstructed coronary arteries. Our results suggest that abnormal coronary vasomotion plays pathogenic role in this setting and that the ERG test might be useful to identify patients with cardiac symptoms, despite normal coronaries.
Results: Baseline clinical characteristics were similar between the two groups except the Low dose group had more elderly (Ͼ 50 years), diabetes mellitus and previous myocardial infarction (MI). During the Ach provocation test, the incidence of atrio-ventricular (AV) block, severe CAS (Ͼ70% stenosis by QCA), multi-vessel spasm and diffuse spasm were more frequent in low dose group (Table) . Conclusions: In our study, we found that pts showing significant CAS to lower Ach dose showed more chance to have severe, diffuse and mulitvessel spasm during the test. Special care with intensive medical therapy should be considered who showed significant Ach response to lower Ach dose as compared with those responded to higher Ach dose. Background: Beta blockers (BB) are widely used to control hypertension. It is well known that BB may lead to significant vasospasm. However, the impact of chronic administration of BB on clinical and angiographic characteristics during acetylcholine (Ach) provocation test is not clarified yet. Methods: A total 3034 consecutive patients (pts) underwent coronary angiography with Ach provocation test from January 2004 to August 2010 were enrolled for this study. Ach was injected in incremental doses of 20, 50, 100g into the left coronary artery. Significant coronary artery spasm (CAS) was defined as focal or diffuse severe transient luminal narrowing (Ͼ70%) with/without chest pain or ST-T change on ECG. A total 1394 pts (45.9%) showed positive provocation tests. Among the (ϩ) provocation test pts, we compared the clinical and angiographic characteristics of patients with beta-blocker to those without beta-blocker in pts with myocardial infarction. Results: The baseline clinical and procedural characteristics are well balanced between the two groups. There was no difference in the incidence of myocardial bridges, chest pain, ischemic ECG changes and atrioventricular (AV) block on ECG, incidence of baseline spasm, severe vasospasm, multi-vessel involvements during the Ach provocation test were similar in both groups Conclusions: The use of beta blocker in pts with vasospastic angina was not associated with worse clinical and angiographic parameters during the Ach provocation test. BB may be safely used in pts with vasospastic angina. 
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Implantation of Sirolimus-Eluting Stent in Patients with
Background:
The recent study has shown that an implantation of sirolimus-eluting stent (SES) is associated with late restenosis, i.e., late catch-up phenomenon. We investigated long-term angiographic outcome in patients with vasospastic angina (VSA) treated with the SES. Methods: Subjects were patients who had undergone an ergonovine-provocation test for chest pain, and were subsequently treated with an SES or bare-metal stent (BMS) because of a progression of coronary artery stenosis. Patients were divided into four groups: SES with vasospasm (SES-V, nϭ26); SES without vasospasm (SES-NV, nϭ53); BMS with vasospasm (BMS-V, nϭ28); and BMS without vasospasm (BMS-NV, nϭ46). Coronary angiography was performed at 8 months (mid-term follow-up) and 20 months (long-term follow-up) after the implantation of the stent. Results: As shown in the figure, the SES implantation was associated with a reduction of minimum lumen diameter (MLD) at the long-term follow-up, indicating late catch-up phenomenon. This phenomenon was more obvious in patients with VSA than in those without (pϽ0.05). Both BMS groups showed a reduction in MLD at the mid-term follow-up compared with immediately after the intervention. This reduction had regressed at the long-term follow-up, and that was unrelated to VSA. The rate of stent edge restenosis compared with stent body restenosis in the SES-V group (87.3%) was higher than that in the SES-NV group (25.0%, pϽ0.05), suggesting the association of vasospasm with stent restenosis.
Conclusions:
The SES implantation may be associated with high rate of late restenosis in patients with vasospastic angina. 
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